Oscar Health, Inc. Stock Prediction and Forecast [OSCR]
1 extracted signal · 1 resolved · 0 still active
StockInvest.usIndependent analyst profile- Source published
- 16 Sept 2025, 03:21 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC
![Video preview for Oscar Health, Inc. Stock Prediction and Forecast [OSCR]](https://i.ytimg.com/vi/ztd8c66a-bY/hqdefault.jpg)
AI-generated source summary
The analysis of Oscar Health (OSCR) stock indicates a mixed outlook. Since August 15, 2025, the system has rated the stock as a buy candidate with a score of 1.21. Those following the analysis would have seen gains of nearly 20% since the initial identification, averaging 0.94% daily. The stock is in a wide horizontal trend, expecting movements within it. The three-month trend indicates a potential change of 0.26% with possible returns ranging from -27.97% to 15.02%. The 12-month projection suggests a -7.28% change, varying between -45.86% and 4.40%. For the last trading day, the stock decreased by 3.10%, closing at $18.73, fluctuating 4.80% with a low of $18.32 and a high of $19.20, even with increase on Volume by 2 million shares. Analyst ratings are generally 'Strong Sell'. A stop-loss is recommended at $17.85(-4.70%). Short-term sell signal is presented and long-term is buy.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
StockInvest.us
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.
